RT Journal Article SR Electronic T1 The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites JF ERJ Open Research JO erjor FD European Respiratory Society SP 00127-2017 DO 10.1183/23120541.00127-2017 VO 4 IS 1 A1 Schneider, Elena K. A1 McQuade, Rachel M. A1 Carbone, Vincenzo C. A1 Reyes-Ortega, Felisa A1 Wilson, John W. A1 Button, Brenda A1 Saito, Ayame A1 Poole, Daniel P. A1 Hoyer, Daniel A1 Li, Jian A1 Velkov, Tony YR 2018 UL http://openres.ersjournals.com/content/4/1/00127-2017.abstract AB Ivacaftor–lumacaftor and ivacaftor are two new breakthrough cystic fibrosis transmembrane conductance modulators.The interactions of ivacaftor and its two metabolites hydroxymethylivacaftor (iva-M1) and ivacaftorcarboxylate (iva-M6) with neurotransmitter receptors were investigated in radioligand binding assays.Ivacaftor displayed significant affinity to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT2C receptor (pKi=6.06±0.03), β3-adrenergic receptor (pKi=5.71±0.07), δ-opioid receptor (pKi=5.59±0.06) and the dopamine transporter (pKi=5.50±0.20); iva-M1 displayed significant affinity to the 5-HT2C receptor (pKi=5.81±0.04) and the muscarinic M3 receptor (pKi=5.70±0.10); iva-M6 displayed significant affinity to the 5-HT2A receptor (pKi=7.33±0.05). The in vivo central nervous system activity of ivacaftor (40 mg·kg−1 intraperitoneally for 21 days) was assessed in a chronic mouse model of depression. In the forced swim test, the ivacaftor-treated group displayed decreased immobility (52.8±7.6 s), similarly to fluoxetine (33.8±11.0 s), and increased climbing/swimming activity (181.5±9.2 s). In the open field test, ivacaftor produced higher locomotor activity than the fluoxetine group, measured both as mean number of paw touches (ivacaftor 81.1±9.6 versus fluoxetine 57.9±9.5) and total distance travelled (ivacaftor 120.6±16.8 cm versus fluoxetine 84.5±16.0 cm) in 600 s. Treatment of 23 cystic fibrosis patients with ivacaftor–lumacaftor resulted in significant improvements in quality of life (including anxiety) in all five domains of the AweScoreCF questionnaire (p=0.092–0.096).Our findings suggest ivacaftor displays potential clinical anxiolytic and stimulating properties, and may have beneficial effects on mood.The novel CFTR potentiator ivacaftor displays potential pre-clinical and clinical anxiolytic and antidepressant properties, which may have beneficial effects on mood and well-being in CF patients receiving ivacaftor or ivacaftor–lumacaftor therapy http://ow.ly/thK430iaigr